First Time Loading...

JW (Cayman) Therapeutics Co Ltd
HKEX:2126

Watchlist Manager
JW (Cayman) Therapeutics Co Ltd Logo
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Watchlist
Price: 1.87 HKD 1.63% Market Closed
Updated: May 9, 2024

Net Margin
JW (Cayman) Therapeutics Co Ltd

-441.7%
Current
-665%
Average
-8.9%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-441.7%
=
Net Income
-768m
/
Revenue
173.9m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
CN
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
771.2m HKD
-442%
US
Abbvie Inc
NYSE:ABBV
283.6B USD
9%
US
Amgen Inc
NASDAQ:AMGN
168.1B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
107.9B USD
37%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
106.8B USD
29%
AU
CSL Ltd
ASX:CSL
133.8B AUD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
80.8B USD
2%
US
Moderna Inc
NASDAQ:MRNA
47.5B USD
-116%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-33%
US
Biogen Inc
NASDAQ:BIIB
32.2B USD
12%
KR
Celltrion Inc
KRX:068270
39.3T KRW
25%
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Country CN
Market Cap 771.2m HKD
Net Margin
-442%
Abbvie Inc
NYSE:ABBV
Country US
Market Cap 283.6B USD
Net Margin
9%
Amgen Inc
NASDAQ:AMGN
Country US
Market Cap 168.1B USD
Net Margin
13%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Country US
Market Cap 107.9B USD
Net Margin
37%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Country US
Market Cap 106.8B USD
Net Margin
29%
CSL Ltd
ASX:CSL
Country AU
Market Cap 133.8B AUD
Net Margin
17%
Gilead Sciences Inc
NASDAQ:GILD
Country US
Market Cap 80.8B USD
Net Margin
2%
Moderna Inc
NASDAQ:MRNA
Country US
Market Cap 47.5B USD
Net Margin
-116%
Seagen Inc
NASDAQ:SGEN
Country US
Market Cap 43.1B USD
Net Margin
-33%
Biogen Inc
NASDAQ:BIIB
Country US
Market Cap 32.2B USD
Net Margin
12%
Celltrion Inc
KRX:068270
Country KR
Market Cap 39.3T KRW
Net Margin
25%

Profitability Report

View the profitability report to see the full profitability analysis for JW (Cayman) Therapeutics Co Ltd.

Full Profitability Report

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-441.7%
=
Net Income
-768m
/
Revenue
173.9m
What is the Net Margin of JW (Cayman) Therapeutics Co Ltd?

Based on JW (Cayman) Therapeutics Co Ltd's most recent financial statements, the company has Net Margin of -441.7%.

ALPHA SPREAD
Join more than 135,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.